Skip to main content
logo
Labcorp Holdings Inc. (LH)
NYSE: LH · Real-Time Price · USD
318.13
-4.46 (-1.38%)
Aug 14, 2026, 4:00 PM EDT - Market closed

Labcorp Holdings Revenue by Segment

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics
11.16B11.01B10.88B10.74B10.52B10.30B10.15B9.91B
Diagnostics Growth
6.06%6.92%7.19%8.43%8.53%8.26%7.82%5.91%
Drug Development
3.21B3.16B3.10B3.07B3.01B2.93B2.92B2.85B
Drug Development Growth
6.58%7.65%6.01%7.78%6.32%3.87%-16.80%-32.26%

Operating Income by Segment

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics
1.85B1.81B1.78B1.72B1.66B1.62B1.61B1.60B
Diagnostics Growth
11.69%12.08%10.81%7.48%3.61%3.08%0.95%-1.48%
Drug Development
531.20M512.30M498.50M493.20M481.90M466.00M459.00M437.20M
Drug Development Growth
10.23%9.94%8.61%12.81%13.31%10.30%2.80%-19.93%
General Corporate Expenses
-284.50M-282.90M-276.80M-276.30M-274.20M-268.70M-268.30M-269.00M

Operating Expense Breakdown

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Selling, General, and Administrative
2.22B2.22B2.22B2.27B2.29B2.27B2.23B2.17B
Selling, General, and Administrative Growth
-3.05%-2.04%-0.61%4.85%7.74%9.41%5.30%2.18%
Amortization
295.80M286.00M280.00M277.80M272.00M265.90M256.40M245.20M
Amortization Growth
8.75%7.56%9.20%13.30%14.67%17.40%8.78%3.42%
Restructuring and Other
128.20M127.20M127.20M27.80M39.90M47.40M46.00M52.90M
Restructuring and Other Growth
221.30%168.35%176.52%-47.45%-5.90%1.72%-8.37%21.33%
Impairments
4.30M4.30M4.30M3.50M2.80M2.80M5.30M336.30M
Impairments Growth
53.57%53.57%-18.87%-98.96%-99.19%-99.20%-98.48%17.79%